Strategies for durable β cell replacement in type 1 diabetes | Science
CRISPR Therapeutics on Twitter: "Today, @CRISPRTX and @ViaCyte announced the approval of our Clinical Trial Application (CTA) for type 1 diabetes (T1D). Read more here: https://t.co/EBzHePL5zG https://t.co/GcJnG9u8fJ" / Twitter
The Most Innovative Ways to Use CRISPR | OpenMind
Stem Cells and the Search For a Type 1 Diabetes Cure
CRISPR, ViaCyte begin dosing in phase 1 trial of gene-edited therapy for type 1 diabetes | Seeking Alpha
Reversing diabetes with CRISPR and patient-derived stem cells | Fierce Biotech
New CRISPR/Cas9 Technique to Potentially Cure Type 1 Diabetes Mellitus - European Medical Journal
CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review | PLOS ONE
CRISPR-based genome editing in primary human pancreatic islet cells | Nature Communications
ViaCyte and CRISPR Introduce New Stem Cell Therapy for Type 1 Diabetes
A genome-wide CRISPR screen identifies regulators of beta cell function involved in type 2 diabetes risk | bioRxiv
Forscher heilen Diabetes bei Mäusen mit genkorrigierten menschlichen...
CRISPR Therapeutics and ViaCyte Tackling Type 1 Diabetes - YouTube
News: First CRISPR Therapy for Type 1 Diabetes Set to Enter Clinical Trial - CRISPR Medicine
Frontiers | Functional Genomics in Pancreatic β Cells: Recent Advances in Gene Deletion and Genome Editing Technologies for Diabetes Research
ActoBio's Cheese-Producing Bacteria Could Reverse Type 1 Diabetes
CRISPR-Cas9 successfully reverses obesity in mice
Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes | Nature Metabolism
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis | NEJM
Looking into the possibilities of cure of the type 2 diabetes mellitus by nanoparticle-based RNAi and CRISPR-Cas9 system: A review - ScienceDirect
Frontiers | Functional Genomics in Pancreatic β Cells: Recent Advances in Gene Deletion and Genome Editing Technologies for Diabetes Research
Sweet Spot: CRISPR Therapeutics, ViaCyte Dose First Patient with Cell Therapy for Type 1 Diabetes
Target gene activation via CRISPR/Cas9 used to treat type 1 diabetes, muscular dystrophy, and acute kidney disease in mouse models : r/science
Type-2 Diabetes and Gene Therapy: The Promise of CRISPR Gene Therapy in type-2 Diabetes Mellitus - Open Access Pub
